Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2010

Open Access 01-12-2010 | Research

The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study

Authors: Dimitrios Panidis, Konstantinos Tziomalos, Ekaterini Koiou, Eleni A Kandaraki, Elena Tsourdi, Dimitrios Delkos, Emmanuil Kalaitzakis, Ilias Katsikis

Published in: Reproductive Biology and Endocrinology | Issue 1/2010

Login to get access

Abstract

Background

Lipocalin-2 is a novel adipokine that appears to play a role in the development of insulin resistance. Serum lipocalin-2 levels are elevated in obese patients. Obesity and insulin resistance are cardinal characteristics of the polycystic ovary syndrome (PCOS). However, there are limited data on serum lipocalin-2 levels in patients with PCOS. The aim of the present study was to assess serum lipocalin-2 levels in PCOS.

Methods

We studied 200 patients with PCOS and 50 healthy female volunteers.

Results

Serum lipocalin-2 levels were slightly higher in women with PCOS compared with controls (65.4 +/- 34.3 vs. 60.3 +/- 26.0 ng/ml, respectively) but this difference did not reach statistical significance. In contrast, lipocalin-2 levels were higher in overweight/obese women with PCOS than in normal weight women with the syndrome (76.2 +/- 37.3 vs. 54.5 +/- 27.2 ng/ml, respectively; p < 0.001). Serum lipocalin-2 levels were also higher in overweight/obese controls compared with normal weight controls (70.1 +/- 24.9 vs. 50.5 +/- 23.7 ng/ml, respectively; p = 0.004). In the total study population (patients with PCOS and controls), lipocalin-2 levels were independently correlated with the body mass index (p < 0.001). In women with PCOS, lipocalin-2 levels were independently correlated with the waist (p < 0.001).

Conclusions

Obesity is associated with elevated serum lipocalin-2 levels. In contrast, PCOS does not appear to affect lipocalin-2 levels.
Appendix
Available only for authorised users
Literature
1.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004, 81: 19-25.
2.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004, 19: 41-47. 10.1093/humrep/deh098.CrossRef
3.
Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN, PCOS/Troglitazone Study Group: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001, 86: 1626-1632. 10.1210/jc.86.4.1626.PubMed
4.
Legato MJ: Gender-specific aspects of obesity. Int J Fertil Womens Med. 1997, 42: 184-197.PubMed
5.
6.
Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997, 18: 774-800. 10.1210/er.18.6.774.PubMed
7.
Goodarzi MO, Korenman SG: The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril. 2003, 80: 255-258. 10.1016/S0015-0282(03)00734-9.CrossRefPubMed
8.
Nestler JE, Jakubowicz DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997, 82: 4075-4079. 10.1210/jc.82.12.4075.PubMed
9.
Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991, 72: 83-89. 10.1210/jcem-72-1-83.CrossRefPubMed
10.
Deslypere JP, Verdonck L, Vermeulen A: Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab. 1985, 61: 564-570. 10.1210/jcem-61-3-564.CrossRefPubMed
11.
Peltoketo H, Luu-The V, Simard J, Adamski J: 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol. 1999, 23: 1-11. 10.1677/jme.0.0230001.CrossRefPubMed
12.
Triebel S, Bläser J, Reinke H, Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992, 314: 386-388. 10.1016/0014-5793(92)81511-J.CrossRefPubMed
13.
Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993, 268: 10425-10432.PubMed
14.
Cowland JB, Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997, 45: 17-23. 10.1006/geno.1997.4896.CrossRefPubMed
15.
Kratchmarova I, Kalume DE, Blagoev B, Scherer PE, Podtelejnikov AV, Molina H, Bickel PE, Andersen JS, Fernandez MM, Bunkenborg J, Roepstorff P, Kristiansen K, Lodish HF, Mann M, Pandey A: A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics. 2002, 1: 213-222. 10.1074/mcp.M200006-MCP200.CrossRefPubMed
16.
Liu Q, Nilsen-Hamilton M: Identification of a new acute phase protein. J Biol Chem. 1995, 270: 22565-22570. 10.1074/jbc.270.38.22565.CrossRefPubMed
17.
Meheus LA, Fransen LM, Raymackers JG, Blockx HA, Van Beeumen JJ, Van Bun SM, Van de Voorde A: Identification by microsequencing of lipopolysaccharide-induced proteins secreted by mouse macrophages. J Immunol. 1993, 151: 1535-1547.PubMed
18.
Sunil VR, Patel KJ, Nilsen-Hamilton M, Heck DE, Laskin JD, Laskin DL: Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. Exp Mol Pathol. 2007, 83: 177-187. 10.1016/j.yexmp.2007.03.004.PubMedCentralCrossRefPubMed
19.
Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, Yan ZQ: Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol. 2006, 169: 2245-2253. 10.2353/ajpath.2006.050706.PubMedCentralCrossRefPubMed
20.
Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, Yarmush ML: Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol Bioeng. 2005, 91: 502-515. 10.1002/bit.20535.CrossRefPubMed
21.
Huang HL, Chu ST, Chen YH: Ovarian steroids regulate 24p3 expression in mouse uterus during the natural estrous cycle and the preimplantation period. J Endocrinol. 1999, 162: 11-19. 10.1677/joe.0.1620011.CrossRefPubMed
22.
Devireddy LR, Teodoro JG, Richard FA, Green MR: Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science. 2001, 293: 829-834. 10.1126/science.1061075.CrossRefPubMed
23.
Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A: Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007, 53: 34-41. 10.1373/clinchem.2006.075614.CrossRefPubMed
24.
Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG: Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol. 2008, 158: 203-207. 10.1530/EJE-07-0633.CrossRefPubMed
25.
Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D: Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009, 296: E238-243. 10.1152/ajpendo.90684.2008.CrossRefPubMed
26.
Morley JE, Patrick P, Perry HM: Evaluation of assays available to measure free testosterone. Metabolism. 2002, 5: 554-559. 10.1053/meta.2002.31975.CrossRef
27.
Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 12-19. 10.1007/BF00280883.CrossRef
28.
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85: 2402-2410. 10.1210/jc.85.7.2402.CrossRefPubMed
29.
Devarajan P: Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury. Nephrol Dial Transplant. 2008, 23: 3737-3743. 10.1093/ndt/gfn531.PubMedCentralCrossRefPubMed
30.
Pervaiz S, Brew K: Homology of beta-lactoglobulin, serum retinol-binding protein, and protein HC. Science. 1985, 228: 335-337. 10.1126/science.2580349.CrossRefPubMed
31.
Pervaiz S, Brew K: Homology and structure-function correlations between alpha 1-acid glycoprotein and serum retinol-binding protein and its relatives. FASEB J. 1987, 1: 209-214.PubMed
32.
Fischbach MA, Lin H, Zhou L, Yu Y, Abergel RJ, Liu DR, Raymond KN, Wanner BL, Strong RK, Walsh CT, Aderem A, Smith KD: The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2. Proc Natl Acad Sci USA. 2006, 103: 16502-16507. 10.1073/pnas.0604636103.PubMedCentralCrossRefPubMed
33.
Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J: An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002, 10: 1045-1056. 10.1016/S1097-2765(02)00710-4.CrossRefPubMed
34.
Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004, 432: 917-921. 10.1038/nature03104.CrossRefPubMed
35.
Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2006, 103: 1834-1839. 10.1073/pnas.0510847103.PubMedCentralCrossRefPubMed
36.
Diamanti-Kandarakis E, Panidis D: Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol. 2007, 67: 735-742. 10.1111/j.1365-2265.2007.02954.x.CrossRef
37.
DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237: E214-E223.PubMed
38.
Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G: Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89: 1273-1276. 10.1210/jc.2003-031205.CrossRefPubMed
39.
Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I: Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?. Eur J Endocrinol. 2008, 158: 525-531. 10.1530/EJE-07-0822.CrossRefPubMed
40.
Cakal E, Ozkaya M, Engin-Ustun Y, Ustun Y: Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. J Endocrinol Invest. 2010, e-pub ahead of print 28 May 2007; PMID: 20511727
41.
Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994, 94: 2493-2503. 10.1172/JCI117619.PubMedCentralCrossRefPubMed
42.
Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998, 32: 368-372. 10.1016/S0735-1097(98)00250-2.CrossRefPubMed
43.
Tayebjee MH, Lip GY, MacFadyen RJ: Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem. 2005, 12: 917-925. 10.2174/0929867053507270.CrossRefPubMed
44.
Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005, 391: 441-448. 10.1042/BJ20051020.PubMedCentralCrossRefPubMed
45.
Yan L, Borregaard N, Kjeldsen L, Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001, 276: 37258-37265. 10.1074/jbc.M106089200.CrossRefPubMed
46.
Leclercq A, Houard X, Philippe M, Ollivier V, Sebbag U, Meilhac O, Michel JB: Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol. 2007, 82: 1420-1429. 10.1189/jlb.1106671.CrossRefPubMed
47.
Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thorén P, Hansson GK: Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006, 26: 136-142. 10.1161/01.ATV.0000193567.88685.f4.CrossRefPubMed
Metadata
Title
The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study
Authors
Dimitrios Panidis
Konstantinos Tziomalos
Ekaterini Koiou
Eleni A Kandaraki
Elena Tsourdi
Dimitrios Delkos
Emmanuil Kalaitzakis
Ilias Katsikis
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2010
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/1477-7827-8-151

Other articles of this Issue 1/2010

Reproductive Biology and Endocrinology 1/2010 Go to the issue

Research

Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer

Research

Family incidence of endometriosis in first-, second-, and third-degree relatives: case-control study

Research

Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status

Research

Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway

Methodology

Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist

Research

Characteristics of temporal patterns of cortisol and luteinizing hormone in primiparous, postpartum, anovular, suckled, beef cows exposed acutely to bulls